Innocrin Pharmaceuticals

About Innocrin Pharmaceuticals

Innocrin Pharmaceuticals, Inc. was a clinical-stage pharmaceutical company that focused on developing treatments for castration-resistant prostate cancer (CRPC) and breast cancer. The company was founded in 2004 and was based in Durham, North Carolina.

The company's lead product candidate was seviteronel (INO-464), an oral, selective CYP17 lyase and androgen receptor (AR) inhibitor. This dual-mechanism approach was designed to treat cancers that have become resistant to other hormonal therapies. By inhibiting both CYP17 lyase and the androgen receptor, seviteronel aimed to block the pathways that fuel the growth of these hormone-dependent cancers.

Innocrin's business model centered on the discovery, development, and eventual commercialization of its therapeutic candidates. The company operated in the highly competitive oncology market, targeting patient populations with significant unmet medical needs. Its primary clients would have been patients with advanced, hormone-resistant breast and prostate cancers. The company's revenue model was contingent on successfully navigating the clinical trial process, gaining regulatory approval, and then marketing its drugs to healthcare providers.

Fred Eshelman, a notable figure in the pharmaceutical industry, was a key founder and investor through his firm, Eshelman Ventures LLC. His extensive experience in founding and leading pharmaceutical companies provided significant strategic guidance to Innocrin. The company's pipeline and intellectual property were originally developed by scientists at the University of Kansas.